Viking Therapeutics, Inc. (VKTX) shareholders
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (7.70%) | 9,539,067 | 7.70% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Capital Management | 5,877,263 | 5.08% | 13G (passive) | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (5.10%) | 5,772,051 | 5.10% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VKTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 6,335,756 | 4.97% | $247.16M | +311,003 | 0.01% |
| BlackRock, Inc. | 6,189,649 | 4.85% | $241.46M | −690,641 | 0.00% |
| State Street Corp | 5,606,394 | 4.40% | $218.71M | +1,210,837 | 0.01% |
| Vanguard Capital Management LLC | 5,053,663 | 3.96% | $197.14M | +41,161 | 0.00% |
| Vanguard Portfolio Management LLC | 4,484,263 | 3.52% | $174.93M | +19,965 | 0.01% |
| Two Sigma Investments, LP | 3,937,414 | 3.09% | $153.60M | −494,728 | 0.11% |
| Morgan Stanley | 3,486,040 | 2.73% | $135.99M | +472,112 | 0.01% |
| Ameriprise Financial Inc | 2,156,083 | 1.69% | $84.11M | +477,338 | 0.02% |
| Geode Capital Management, LLC | 2,097,981 | 1.65% | $81.87M | +15,914 | 0.00% |
| American Century Companies Inc | 1,816,050 | 1.42% | $70.84M | −262,527 | 0.03% |
| D. E. Shaw & Co., Inc. | 1,605,994 | 1.26% | $62.65M | −70,719 | 0.03% |
| Bnp Paribas Arbitrage, Snc | 981,700 | 0.77% | $38.30M | +441,201 | 0.01% |
| Citadel Advisors LLC | 951,515 | 0.75% | $37.12M | −310,706 | 0.00% |
| Goldman Sachs Group Inc | 942,841 | 0.74% | $36.78M | −17,729 | 0.00% |
| UBS Group AG | 936,055 | 0.73% | $36.52M | −411,417 | 0.00% |
| JPMorgan Chase & Co | 915,185 | 0.72% | $36.39M | +429,482 | 0.00% |
| Jane Street Group, LLC | 899,558 | 0.71% | $35.09M | +150,609 | 0.00% |
| Susquehanna International Group, Llp | 816,367 | 0.64% | $31.85M | +110,558 | 0.00% |
| Raymond James Financial Inc | 794,660 | 0.62% | $31.00M | −1,280,743 | 0.01% |
| Vanguard Fiduciary Trust Co | 732,047 | 0.57% | $28.56M | +21,635 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 434 | 76M | 59.4% | 75 / 144 | 131 / 50 | 9M | 7M |
| Q1 2026 | 414 | 73M | 57.5% | 67 / 155 | 118 / 71 | 21M | 10M |
| Q4 2025 | 426 | 72M | 56.5% | 112 / 115 | 134 / 44 | 13M | 14M |
| Q3 2025 | 370 | 74M | 57.9% | 51 / 142 | 108 / 69 | 13M | 16M |
| Q2 2025 | 391 | 77M | 60.3% | 82 / 149 | 109 / 59 | 12M | 13M |
| Q1 2025 | 372 | 78M | 61.3% | 66 / 161 | 99 / 99 | 12M | 15M |
| Q4 2024 | 408 | 82M | 64.3% | 82 / 147 | 127 / 88 | 10M | 13M |
| Q3 2024 | 422 | 86M | 67.5% | 95 / 178 | 101 / 57 | 17M | 8M |
| Q2 2024 | 387 | 83M | 64.9% | 91 / 165 | 102 / 72 | 16M | 17M |
| Q1 2024 | 373 | 83M | 65.5% | 202 / 78 | 86 / 26 | 27M | 23M |
| Q4 2023 | 197 | 79M | 61.6% | 48 / 61 | 54 / 30 | 12M | 11M |
| Q3 2023 | 179 | 77M | 60.7% | 31 / 63 | 49 / 43 | 12M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
269 funds held VKTX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VKTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,587,998 | 2.81% | $139.97M | 1.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,500,175 | 2.74% | $136.54M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,528,235 | 1.98% | $98.63M | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,458,461 | 1.14% | $56.89M | 0.12% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,333,178 | 1.05% | $52.01M | 0.05% | Jun 30, 2026 |
| Heritage Fund | 1,331,574 | 1.04% | $42.26M | 0.80% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund | 1,062,178 | 0.83% | $34.78M | 0.10% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 598,010 | 0.47% | $19.58M | 0.05% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 555,687 | 0.44% | $18.19M | 0.08% | May 31, 2026 |
| Select Health Care Portfolio | 540,000 | 0.42% | $17.68M | 0.31% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 537,400 | 0.42% | $17.06M | 0.23% | Jul 31, 2026 |
| iShares Russell Mid-Cap ETF | 467,194 | 0.37% | $18.23M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 450,187 | 0.35% | $14.29M | 0.65% | Jul 31, 2026 |
| Vanguard Explorer Fund | 444,125 | 0.35% | $14.10M | 0.06% | Jul 31, 2026 |
| Fidelity Mid Cap Index Fund | 428,648 | 0.34% | $13.61M | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian Lian | President & CEO, Director | 2,572,441 | 2.02% | Jul 29, 2026 |
| Greg Zante | Chief Financial Officer | 212,204 | 0.17% | Jul 29, 2026 |
| Marianna Mancini | Chief Operating Officer | 422,760 | 0.33% | Jul 29, 2026 |
| Hubert C. Chen | Chief Medical Officer | – | – | Jun 3, 2026 |
| Neil William Aubuchon | Chief Commercial Officer | 4,475 | 0.00% | Mar 10, 2026 |
| Dorothy Elizabeth Kelly-Gemmell | Director | 6,333 | 0.00% | Aug 7, 2026 |
| Lawson Macartney | Director | 51,115 | 0.04% | Jan 5, 2026 |
| Matthew W. Foehr | Director | 132,036 | 0.10% | Jan 5, 2026 |
| Sarah Kathryn Rouan | Director | 4,390 | 0.00% | Jan 5, 2026 |
| Charles A. Rowland Jr | Director | 33,150 | 0.03% | Jan 5, 2026 |
| J. Matthew Singleton | Director | 12,650 | 0.01% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dorothy Elizabeth Kelly-Gemmell Director | Aug 1, 2026 | Award | +6,333 | – | – | 6,333 |
| Brian Lian President & CEO, Director | Jul 29, 2026 | Sale | −148,517 | $33.32 | $4.95M | 2,572,441 |
| Marianna Mancini Chief Operating Officer | Jul 29, 2026 | Sale | −18,217 | $33.47 | $609.72K | 422,760 |
| Greg Zante Chief Financial Officer | Jul 29, 2026 | Sale | −21,217 | $33.47 | $710.13K | 212,204 |
| Brian Lian President & CEO, Director | Jul 28, 2026 | Award | +221,667 | – | – | 2,720,958 |
| Marianna Mancini Chief Operating Officer | Jul 28, 2026 | Award | +31,667 | – | – | 440,977 |
| Greg Zante Chief Financial Officer | Jul 28, 2026 | Award | +31,667 | – | – | 233,421 |
| Neil William Aubuchon Chief Commercial Officer | Mar 10, 2026 | Buy | +4,475 | $33.50 | $149.91K | 4,475 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −1,500 | $32.09 | $48.14K | 189,891 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −10,300 | $34.24 | $352.67K | 191,371 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −13,900 | $33.38 | $463.98K | 201,671 |
| Greg Zante Chief Financial Officer | Jan 5, 2026 | Sale | −31,961 | $32.30 | $1.03M | 215,571 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −1,600 | $35.07 | $56.11K | 409,190 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −10,500 | $34.22 | $359.31K | 410,790 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −13,600 | $33.37 | $453.83K | 421,290 |
| Marianna Mancini Chief Operating Officer | Jan 5, 2026 | Sale | −31,961 | $32.29 | $1.03M | 434,890 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −132,454 | $32.29 | $4.28M | 2,600,246 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −41,276 | $34.22 | $1.41M | 2,505,691 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −53,279 | $33.38 | $1.78M | 2,546,967 |
| Brian Lian President & CEO, Director | Jan 5, 2026 | Sale | −6,400 | $35.07 | $224.45K | 2,499,291 |
| Sarah Kathryn Rouan Director | Jan 2, 2026 | Award | +3,150 | – | – | 4,390 |
| J. Matthew Singleton Director | Jan 2, 2026 | Award | +3,150 | – | – | 12,650 |
| Lawson Macartney Director | Jan 2, 2026 | Award | +3,150 | – | – | 51,115 |
| Charles A. Rowland Jr Director | Jan 2, 2026 | Award | +3,150 | – | – | 33,150 |
| Greg Zante Chief Financial Officer | Jan 2, 2026 | Award | +32,049 | – | – | 247,532 |
| Greg Zante Chief Financial Officer | Jan 2, 2026 | Award | +41,000 | – | – | 215,483 |
| Marianna Mancini Chief Operating Officer | Jan 2, 2026 | Award | +32,049 | – | – | 466,851 |
| Marianna Mancini Chief Operating Officer | Jan 2, 2026 | Award | +41,000 | – | – | 434,802 |
| Brian Lian President & CEO, Director | Jan 2, 2026 | Award | +78,400 | – | – | 2,508,620 |
| Brian Lian President & CEO, Director | Jan 2, 2026 | Award | +224,080 | – | – | 2,732,700 |
| Matthew W. Foehr Director | Jan 2, 2026 | Sale | −16,000 | $35.11 | $561.76K | 132,036 |
| Matthew W. Foehr Director | Jan 2, 2026 | Option exercise | +16,000 | $3.33 | $53.28K | 148,036 |
| Matthew W. Foehr Director | Jan 2, 2026 | Award | +3,150 | – | – | 135,186 |
| Marianna Mancini Chief Operating Officer | Oct 28, 2025 | Sale | −6,185 | $35.00 | $216.48K | 382,467 |
| Brian Lian President & CEO, Director | Oct 28, 2025 | Sale | −38,989 | $35.01 | $1.37M | 2,419,109 |
| Greg Zante Chief Financial Officer | Oct 28, 2025 | Sale | −6,185 | $35.00 | $216.48K | 173,592 |
| Marianna Mancini Chief Operating Officer | Oct 27, 2025 | Award | +11,117 | – | – | 388,652 |
| Brian Lian President & CEO, Director | Oct 27, 2025 | Award | +70,084 | – | – | 2,458,098 |
| Greg Zante Chief Financial Officer | Oct 27, 2025 | Award | +11,117 | – | – | 179,777 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +16,000 | $4.48 | $71.68K | 46,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +22,000 | $5.80 | $127.60K | 68,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Award | +22,000 | $4.88 | $107.36K | 90,000 |
| Charles A. Rowland Jr Director | Oct 27, 2025 | Sale | −60,000 | $35.57 | $2.13M | 30,000 |
| Brian Lian President & CEO, Director | Jul 3, 2025 | Sale | −26,889 | $27.80 | $747.51K | 2,388,014 |
| Marianna Mancini Chief Operating Officer | Jul 3, 2025 | Sale | −4,266 | $27.77 | $118.47K | 377,535 |
| Greg Zante Chief Financial Officer | Jul 3, 2025 | Sale | −4,266 | $27.76 | $118.42K | 168,660 |
| Brian Lian President & CEO, Director | Jul 2, 2025 | Award | +48,333 | – | – | 2,414,903 |
| Marianna Mancini Chief Operating Officer | Jul 2, 2025 | Award | +7,667 | – | – | 381,801 |
| Greg Zante Chief Financial Officer | Jul 2, 2025 | Award | +7,667 | – | – | 172,926 |
| Matthew W. Foehr Director | Apr 11, 2025 | Option exercise | +20,786 | $8.00 | $166.29K | 132,036 |
| Sarah Kathryn Rouan Director | Mar 31, 2025 | Buy | +1,240 | $24.15 | $29.95K | 1,240 |
| Sarah Kathryn Rouan Director | Mar 31, 2025 | Buy | +1,240 | $24.15 | $29.95K | 1,240 |
| Brian Lian President & CEO, Director | Jan 6, 2025 | Sale | −175,490 | $42.68 | $7.49M | 2,385,570 |
| Brian Lian President & CEO, Director | Jan 6, 2025 | Sale | −19,000 | $43.32 | $823.08K | 2,366,570 |
| Greg Zante Chief Financial Officer | Jan 6, 2025 | Sale | −45,609 | $42.69 | $1.95M | 169,959 |
| Greg Zante Chief Financial Officer | Jan 6, 2025 | Sale | −4,700 | $43.32 | $203.60K | 165,259 |
| Marianna Mancini Chief Operating Officer | Jan 6, 2025 | Sale | −5,100 | $43.32 | $220.93K | 374,134 |
| Marianna Mancini Chief Operating Officer | Jan 6, 2025 | Sale | −49,115 | $42.69 | $2.10M | 379,234 |
| Brian Lian President & CEO, Director | Jan 3, 2025 | Award | +163,333 | – | – | 2,561,060 |
| Brian Lian President & CEO, Director | Jan 3, 2025 | Award | +92,800 | – | – | 2,397,727 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Viking Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,254 shares on Sep 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Greg Zante Officer | Jul 29, 2026 | 21,217 | $710.14K | Jul 29, 2026 | Performance Stock Units |
| Marianna Mancini Officer | Jul 29, 2026 | 18,217 | $609.64K | Jul 29, 2026 | Performance Stock Units |
| Brian Lian Officer | Jul 29, 2026 | 148,517 | $4.95M | Jul 29, 2026 | Performance Stock Units |
| Brian Lian Officer | Jan 5, 2026 | 233,409 | $7.69M | Jan 5, 2026 | Performance Stock Units |
| Greg Zante Officer | Jan 5, 2026 | 57,661 | $1.90M | Jan 5, 2026 | Performance Stock Units |
| Marianna Mancini Officer | Jan 5, 2026 | 57,661 | $1.90M | Jan 5, 2026 | Restricted stock vesting under a registered plan |
| Matthew W. Foehr Director | Jan 2, 2026 | 16,000 | $561.69K | Jan 2, 2026 | Exercise of options under a registered plan |
| Greg Zante Officer | Oct 28, 2025 | 6,185 | $216.53K | Oct 28, 2025 | Performance Stock Units |
| Marianna Mancini Officer | Oct 28, 2025 | 6,185 | $216.49K | Oct 28, 2025 | Performance Stock Units |
| Brian Lian Officer | Oct 28, 2025 | 38,989 | $1.36M | Oct 28, 2025 | Performance Stock Units |
| Charles A. Rowland Jr Director | Oct 27, 2025 | 60,000 | $2.13M | Oct 27, 2025 | Exercise of options under a registered plan |
| Brian Lian Officer | Jul 3, 2025 | 26,889 | $747.63K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Marianna Mancini Officer | Jul 3, 2025 | 4,266 | $118.47K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Greg Zante Officer | Jul 3, 2025 | 4,266 | $118.43K | Jul 3, 2025 | Restricted stock vesting under a registered plan |
| Marianna Mancini Officer | Jan 6, 2025 | 54,215 | $2.32M | Jan 6, 2025 | Restricted stock vesting under a registered plan |
See a number that looks wrong?